MedTrace Logo

CGM Use in Adults With Type 2 Diabetes on Basal Insulin

NCT05944432 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 470

Last updated 2026-05-19

No results posted yet for this study

Summary

A prospective multi-centre, open-label, two arm, parallel design, superiority, pragmatic, randomised controlled trial, over an 8-month period. The purpose of this study is to determine whether continuous glucose monitoring using FreeStyle Libre 3 will improve HbA1c compared to SMBG over 16 weeks in adults with sub-optimally controlled (HbA1c 7.5-11%) Type 2 diabetes on basal therapy.

Following completion of the 8-month period for all participants, an optional non-interventional follow-up period will assess glycaemic control and treatment patterns over 24 months.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

FreeStyle Libre 3 Continuous Glucose Monitoring System.

Subjects will be randomised to use the FreeStyle Libre 3 system

DEVICE

Self monitoring of blood glucose

Subjects will be randomised to continue with their current glucose monitoring system

Sponsors & Collaborators

  • Abbott Diabetes Care

    lead INDUSTRY

Principal Investigators

  • Pamela Reid · Abbott Diabetes Care Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-14
Primary Completion
2026-02-19
Completion
2027-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05944432 on ClinicalTrials.gov